⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2118014 | 0.98 | DAO (0.45) | — | |
| SCHEMBL8404473 | 0.74 | — | — | |
| SCHEMBL13760002 | 0.73 | — | — | |
| SCHEMBL28072733 | 0.73 | — | — | |
| SCHEMBL10895825 | 0.73 | — | — | |
| SCHEMBL12381075 | 0.73 | DAO (0.45) | — | |
| SCHEMBL15100201 | 0.73 | APP (0.39) | — | |
| SCHEMBL13422405 | 0.73 | DAO (0.45) | — | |
| SCHEMBL1146029 | 0.70 | NOTUM (0.54) | — | |
| SCHEMBL10529744 | 0.70 | APP (0.56) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5962480-A | CONTAINING PYRAN-4-ONE OR PYRID-4-ONE RING | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 1999-10-05 | — | — | US | claimed |
| EP-2834239-B1 | HETEROBICYCLIC COMPOUNDS AS BETA-LACTAMASE INHIBITORS | ENTASIS THERAPEUTICS LTD (GB) | 2017-12-27 | — | — | EP | disclosed |
| US-9623014-B2 | β-lactamase inhibitor compounds | ENTASIS THERAPEUTICS LIMITED (GB) | 2017-04-18 | — | — | US | disclosed |
| EP-2134688-B1 | FLUORINATED DERIVATIVES OF DEFERIPRONE | APOTEX TECHNOLOGIES INC (CA) | 2016-10-05 | — | — | EP | disclosed |
| US-20160175290-A1 | BETA-LACTAMASE INHIBITOR COMPOUNDS | ASTRAZENECA PHARMACEUTICALS LP | 2016-06-23 | — | — | US | disclosed |
| US-9309245-B2 | Beta-lactamase inhibitor compounds | ENTASIS THERAPEUTICS LIMITED (GB) | 2016-04-12 | — | — | US | disclosed |
| US-9238657-B2 | Cephalosporin having catechol group | SHIONOGI & CO., LTD. (JP) | 2016-01-19 | — | — | US | disclosed |
| US-20150148326-A1 | Monobactams | PFIZER (US) | 2015-05-28 | — | — | US | disclosed |
| EP-2646436-B1 | MONOBACTAMS | PFIZER (US) | 2015-05-27 | — | — | EP | disclosed |
| US-20150073011-A1 | Beta-Lactamase Inhibitor Compounds | ASTRAZENECA AB (SE) | 2015-03-12 | — | — | US | disclosed |
| WO-2012073138-A1 | MONOBACTAMS | PFIZER INC. (US) | 2012-06-07 | — | — | WO | disclosed |
| US-20120095061-A1 | Fluorinated Derivatives of Deferiprone | APOTEX TECHNOLOGIES INC. (CA) | 2012-04-19 | — | — | US | disclosed |
| US-8026261-B2 | neurodegenerative diseases; to remove free iron or iron accumulation in neural tissues; iron chelators; improved chemical stability, penetration through blood brain barrier; reacting 3-hydroxy-4-pyridinone/3-hydroxy-4-pyranone derivatives; 1-cyclopropyl-2-difluoromethyl-5-hydroxy-1H-pyridin-4-one | APOTEX TECHNOLOGIES INC. (CA) | 2011-09-27 | — | — | US | disclosed |
| US-20110190254-A1 | CEPHALOSPORIN HAVING CATECHOL GROUP | SHIONOGI & CO., LTD. (JP) | 2011-08-04 | — | — | US | disclosed |
| US-20100076199-A1 | PROCESS FOR THE PREPARATION OF SUBSTITUTED PYRIDONE CARBOXYLIC ACIDS | GE HEALTHCARE AS (NO) | 2010-03-25 | — | — | US | disclosed |
| EP-2134688-A1 | FLUORINATED DERIVATIVES OF DEFERIPRONE | Apotex Technologies Inc. (CA) | 2009-12-23 | — | — | EP | disclosed |
| WO-2008116301-A1 | FLUORINATED DERIVATIVES OF DEFERIPRONE | APOTEX TECHNOLOGIES INC. (CA) | 2008-10-02 | — | — | WO | disclosed |
| US-20080242706-A1 | Fluorinated derivatives of deferiprone | APOTEX TECHNOLOGIES INC. | 2008-10-02 | — | — | US | disclosed |
| US-5962480-A | CONTAINING PYRAN-4-ONE OR PYRID-4-ONE RING | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 1999-10-05 | — | — | US | disclosed |
| EP-0838220-A1 | DRUG FOR AMELIORATING BRAIN DISEASES | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 1998-04-29 | — | — | EP | disclosed |